Stay up-to-date with the latest in the world of psychedelics with our weekly news roundup for week 43 of 2023. Read about the latest research, policy updates, and industry developments in the rapidly growing field of psychedelic science.
CYBIN Announces Grant of Two New United States Patents Protecting Its Deuterated DMT Program
Cybin, a clinical-stage biopharmaceutical company, has received two patent grants from the United States Patent and Trademark Office, providing protection for its deuterated N, N-dimethyltryptamine (DMT) program. The company’s proprietary deuterated DMT compounds, CYB004 and SPL028, are currently in Phase I clinical trials. These compounds are designed to offer an extended DMT psychedelic experience while maintaining a short-duration drug profile. This approach allows for optimized dose formulations for various administration routes and potential therapeutic benefits for patients.
The granted patents protecting the Company’s deuterated DMT program are:
- United States patent no. 11,771,681, which provides composition of matter protection for certain deuterated analogs of DMT; and
- United States patent no. 11,773,062, which provides protection for the medical use and the
Preliminary findings from the clinical studies indicate that both IV CYB004 and SPL028 provide a psychedelic experience lasting less than one hour and are well-tolerated. The company anticipates releasing topline data from these trials in the fourth quarter of 2023.
Cybin’s CEO, Doug Drysdale, emphasized that these patent grants, along with their recent acquisition of Small Pharma Inc., bring their total patent protection to 32 granted patents and over 170 pending applications. This substantial intellectual property portfolio strengthens Cybin’s leadership position in the development of novel tryptamine-based therapeutics, encompassing various aspects, including composition of matter, medical use, synthesis, and drug product protection, which allows them to advance their deuterated programs with confidence.
Eureka! Another California City Decriminalizes Psychedelics
Eureka, California has become the latest city to decriminalize psychedelic medicines. The city council adopted a resolution this week that moves psychedelics (Entheogenic Plants and Fungi) to the lowest priority level for law enforcement.
“… planting, cultivating, purchasing, transporting, distributing, engaging in practices with, or possessing Entheogenic Plants and Fungi or their extracted compounds that are on the Federal Schedule I list … will not be a public safety priority for the City of Eureka.”
B.C. Psychiatrist Resigns Licence After Patient Complains of Abuse During Psychedelic Therapy Study
A psychiatrist in British Columbia, Donna Dryer, has permanently surrendered her medical license in response to a complaint regarding her treatment of a PTSD patient participating in a clinical trial for MDMA-assisted psychotherapy. The disciplinary action came after Dryer admitted to unprofessional conduct, including a conflict of interest, boundary violations, and maintaining a therapeutic relationship despite knowing that her husband and research partner, Richard Yensen, was having a sexual relationship with the patient.
The Multidisciplinary Association for Psychedelic Studies (MAPS), the sponsor of the clinical trial, has described Yensen’s actions as sexual abuse. The patient filed a sexual assault complaint with the police, and although the police recommended unspecified criminal charges in 2022, Crown prosecutors did not approve them.
Videos recorded during the patient’s treatment sessions in the clinical trial depict concerning interactions between Dryer, Yensen, and the distressed patient. These interactions included physical contact and comments of a sexual nature. The patient has raised objections to the terminology used in the College of Physicians and Surgeons of B.C.’s reprimand, particularly the characterization of Yensen’s actions as engaging in “sexual relations.”
Psychedelic Market Update – October 23rd – 27th
|Ticker||Current Price||Week To Date||Year to Date|